Heart Attack News and Research

RSS

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Data shows cost-effectiveness of ZOLL LifeVest Wearable Defibrillator

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that data showing the cost-effectiveness of the LifeVest Wearable Defibrillator was presented in two scientific presentations and posters at the American Heart Association's Scientific Sessions 2011 in Orlando over the weekend.

14 Nov 2011

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

BioVentrix, developer of the PliCath HF System, today announced the achievement of a significant milestone - completion of enrollment in its pilot human clinical trial. PliCath HF is a novel device which enables Epicardial Catheter-based Ventricular Restoration (ECVR).

14 Nov 2011

Studies examine cardiac arrest-information exchange on social media site

Discussion about cardiac arrest on Twitter is common and represents a new opportunity to provide lifesaving information to the public, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The Penn investigators will present two studies examining cardiac arrest-information exchange on the social media site today at the American Heart Association's annual Scientific Sessions.

14 Nov 2011

Professional tooth scaling associated with fewer heart attacks, strokes

Professional tooth scaling was associated with fewer heart attacks and strokes in a study from Taiwan presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Depression linked to heart disease mortality among young people

The negative effects of depression in young people on the health of their hearts may be stronger than previously recognized. Depression or a history of suicide attempts in people younger than 40, especially young women, markedly increases their risk for dying from heart disease, results from a nationwide study have revealed.

14 Nov 2011

Oncostatin M could help heal damaged heart muscle tissue

Oncostatin M regulates the reversion of heart muscle cells into precursor cells and is vitally important for the self-healing powers of the heart

11 Nov 2011

Dramatic rise in obesity, fatty liver disease increases need for transplants

The dramatic rise in obesity is leading to more fatty liver disease in the United States, increasing the need for more transplants at a time when there already is a severe shortage of donated organs.

11 Nov 2011

Classical DCs associated with protection against atherosclerosis

Atherosclerosis, commonly referred to as "hardening of the arteries," is a major risk factor for heart attack and stroke. The cause of atherosclerosis is not well understood but, for some time, chronic inflammatory immune responses have been implicated in driving disease pathology. Now, a new study, published online on November 10th by Cell Press from the journal Immunity, identifies a type of immune cell that is not associated with promoting disease, but with protection against atherosclerosis.

11 Nov 2011

GHSU expert to again coordinate two national diabetes initiatives

Two national efforts supporting diabetes research will again be coordinated by a Georgia Health Sciences University bioinformatics expert.

10 Nov 2011

Treatments can help most HCM patients

Most of the 600,000 Americans with hypertrophic cardiomyopathy (HCM) -- a genetic heart muscle disease -- can live normal life spans, according to the first science-based guideline for diagnosing and treating this disorder.

9 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

RA patients with low levels of inflammation less likely to develop cardiovascular disease

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, patients with rheumatoid arthritis who have low levels of inflammatory disease activity have lower risk for heart complications and stroke.

7 Nov 2011

AHA/ASA honors UH Case Medical Center with Get With The Guidelines-Stroke award

For the third consecutive year, University Hospitals (UH) Case Medical Center has received the American Heart Association/American Stroke Association's Get With The Guidelines--Stroke Gold Plus Quality Achievement Award.

4 Nov 2011

UCSD experts use hybrid OR to perform first-ever coronary revascularization procedure

UC San Diego Sulpizio Cardiovascular Center experts have performed San Diego's first-ever coronary revascularization procedure using a hybrid operating room, the only facility of its kind in the region. The state-of-the-art operating room allows patients to be treated in one place at one time without having to schedule multiple procedures.

4 Nov 2011

Glaxo pays $3 billion to settle investigations involving alleged marketing missteps and Medicaid fraud

GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.

4 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011

First Edition: November 3, 2011

Today's headlines include reports about a bipartisan group of lawmakers who are urging the super committee to consider "all options."

3 Nov 2011

Heart Attack News and Research

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

Data shows cost-effectiveness of ZOLL LifeVest Wearable Defibrillator

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

Studies examine cardiac arrest-information exchange on social media site

Professional tooth scaling associated with fewer heart attacks, strokes

Depression linked to heart disease mortality among young people

Oncostatin M could help heal damaged heart muscle tissue

Dramatic rise in obesity, fatty liver disease increases need for transplants

Classical DCs associated with protection against atherosclerosis

GHSU expert to again coordinate two national diabetes initiatives

Treatments can help most HCM patients

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

MILV subsidiary acquires formula to restore proper kidney function

RA patients with low levels of inflammation less likely to develop cardiovascular disease

AHA/ASA honors UH Case Medical Center with Get With The Guidelines-Stroke award

UCSD experts use hybrid OR to perform first-ever coronary revascularization procedure

Glaxo pays $3 billion to settle investigations involving alleged marketing missteps and Medicaid fraud

Merck’s cholesterol lowering drug gets FDA panel’s vote

The brain and the heart may not be so different after all

First Edition: November 3, 2011

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News